Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is an aggressive, largely chemo-resistant disease with a poor prognosis.
EGFR and VEGF are both overexpressed in pancreatic cancers and thought to contribute to
tumour development and progression. The combination of gemcitabine and capecitabine has
recently been shown to be effective in advanced pancreatic cancer. The combination of
gemcitabine plus erlotinib has also been shown to be effective in advanced pancreatic cancer.
The aim of this study is to assess whether combining a chemotherapy doublet (gemcitabine plus
capecitabine) and a biologic doublet (erlotinib plus bevacizumab) is a safe and effective way
to treat advanced pancreatic cancer by targeting multiple tumour stimulating mechanisms
simultaneously.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Hoffmann-La Roche Professor Cunningham's Clinical Research Fund